IDEAYA Biosciences (IDYA) Share-based Compensation (2018 - 2026)

IDEAYA Biosciences (IDYA) has 9 years of Share-based Compensation data on file, last reported at $161.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 67.98% year-over-year to $161.6 million; the trailing twelve-month figure through Mar 2026 stood at $161.6 million (up 67.98% YoY), and the FY2025 full-year result was $96.2 million, up 6.65% from the prior year.
• Share-based Compensation climbed to $161.6 million in Q1 2026, from -$28.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $161.6 million in Q1 2026 to a low of -$28.1 million in Q4 2025.
• A 5-year average of $25.2 million and a median of $6.3 million in 2024 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 1424.08% in 2025, while the deepest fall reached 396.64% in 2025.
• Tracing IDYA's Share-based Compensation over 5 years: stood at $3.0 million in 2022, then soared by 521.48% to $18.5 million in 2023, then sank by 48.7% to $9.5 million in 2024, then plunged by 396.64% to -$28.1 million in 2025, then soared by 674.35% to $161.6 million in 2026.
• Business Quant data shows IDYA's Share-based Compensation at $161.6 million in Q1 2026, -$28.1 million in Q4 2025, and $108.4 million in Q3 2025.